You are here:

aripiprazole (Abilify)

Advice

following a full submission

aripiprazole prolonged release suspension for injection (Abilify Maintena®) is accepted for use within NHS Scotland.

Indication under review: maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

In a comparative study, aripiprazole prolonged release suspension for injection was as effective as oral aripiprazole in reducing the risk of impending relapse over 26 weeks in stabilised schizophrenic patients.  Weaknesses in the indirect comparison limit the reliability of relative efficacy and safety with prolonged release injection forms of other atypical antipsychotics. 

Drug Details

Drug Name: aripiprazole (Abilify)
SMC Drug ID: 962/14
Manufacturer: Otsuka Pharmaceutical Europe
Indication: Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 May 2014

Back